Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., King, J., Parmar, M., Turner, A. J., Carreira, S., Riisnaes, R., Finneran, L., Hall, E., Ishikawa, Y., Nakai, K., Tunariu, N., Basu, B., Kaiser, M., Lopez, J. S., Minchom, A., de Bono, J. S., & Banerji, U. (2020). intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet oncology, 21(11), 1478–1488. http://access.bl.uk/ark:/81055/vdc_100113642369.0x000017